United States: FDA's Proposal For Naming Biosimilars Pleases Some, Disappoints Others

Last Updated: September 22 2015
Article by Elizabeth L. Callahan and Irena Royzman

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar biological products, but is silent on how to name them. The nonproprietary naming of biosimilars has been an area of controversy because, unlike generic drugs, biosimilar biological products are only biosimilar to and cannot be the same as the originator product. Many have argued that distinct nonproprietary names (also known as proper names) for originator products and their biosimilars are necessary to protect patients. Biosimilar makers have argued that distinct names will impede the adoption of biosimilars.

After years of debate, FDA released a draft guidance that adopts a middle-road approach. Unlike small-molecule drugs, where the branded and generic drugs share the same nonproprietary name, FDA's guidance provides distinct nonproprietary names for biological products. FDA proposes that all biological products carry the nonproprietary name of the originator biological product, along with a unique suffix to identify originator biological products, related biological products, and biosimilar products. But FDA's proposed unique suffix is a random collection of four letters that is neither meaningful nor memorable. It is "devoid of meaning" to address concerns of biosimilar makers that distinctive names will discourage adoption of biosimilars.

The FDA's guidance document has been long-awaited by the healthcare industry. Under the new guidance, healthcare providers will be able to differentiate among biological products to minimize inadvertent substitution of biological products that have not been determined by the FDA to be interchangeable. According to the FDA, the new naming convention is designed to "maximize the success of biosimilar products and interchangeable products and to help ensure the safety of patients receiving biological products licensed under the [Public Health Services] Act."

In practice, the FDA intends to use a "core name" that is shared among all related biological products. For originator biological products, FDA will use the name adopted by the USAN Council for the drug substance as the core name. If the biological product is a related, biosimilar, or interchangeable product, the core name will be the nonproprietary name of the originator biological product, e.g., filgrastim in the case of Amgen's Neupogen. A suffix of four lowercase letters will be added to the core name of each biological product, including the originator product, with a hyphen. The suffix must be a unique series of four letters and may not be promotional, such as making misrepresentations with respect to safety or efficacy. For example, Sandoz's Zarxio, a biosimilar of Amgen's Neupogen product, will have the nonproprietary name "filgrastim-bflm." Zarxio had previously been given the placeholder name "filgrastim-sndz."

According to the FDA, the suffix "will provide a consistent, readily available and recognizable mechanism for patients and health care professionals, including providers and pharmacists, to correctly identify these products." FDA chose a suffix instead of a prefix so that products with the same core name will be grouped together in electronic databases.

The FDA explained that by requiring suffixes for all biological products, including originator products, it intends to promote pharmacovigilance while "avoid[ing] inaccurate perceptions of the safety and effectiveness of biological products based on their licensure pathway." That is, requiring both originator and biosimilar biological products to carry a four-letter suffix will avoid giving medical professionals and patients the impression that biosimilar products differ from the originator products in a clinically meaningful way. The FDA does, however, request feedback from the public as to whether the nonproprietary name for an interchangeable biological product should share the same suffix as the originator product. Comments should be submitted by October 27, 2015.

The FDA is also seeking comment on the best approach to implementing its naming convention for previously licensed products. It has issued a proposed rule to designate nonproprietary names with distinguishing suffixes for six previously licensed biological products. Each of the six products is either an originator biologic for an approved or publicly disclosed biosimilar application or a biological product that is related to one of the originator biologics. The proposed nonproprietary name for Amgen's Neupogen, for example, is "filgrastim-jcwp." Comments on the rule should be submitted by November 12, 2015.

Patient advocacy groups praised FDA's guidance, saying that distinctive names are needed for patient safety. The American College of Rheumatology said that "[d]istinctive names will allow for greater transparency in substitution and notification, making it clear to all parties involved – pharmacists, providers and patients – which drug the patient is receiving." The Global Healthy Living Foundation called FDA's guidance "a major win for patients and physicians." The Biologics Prescribers Collaborative (BPC) also commended FDA's decision to require distinctive names. BPC said that the "prescribers who work every day with biologics – and their patients – are winners from FDA's decision. The agency recognized that distinguishable names are essential to pharmacovigilance, patient safety, and transparency."

The Alliance for Safe Biologic Medicines (ASBM), a group of biotech companies, was supportive of FDA's decision to use distinctive names but thought the guidance did not go far enough. The ASBM called for a "meaningful, intuitive suffix applied consistently to all products by a single manufacturer" as opposed to FDA's proposal for a suffix "devoid of meaning." ASBM pointed to FDA's placeholder name for Sandoz' Zarxio as "filgrastim-sndz" as an example of a nonproprietary name with a meaningful suffix, explaining that the "sndz" suffix was "not only memorable and logical" but also promoted manufacturer accountability by associating the product with its manufacturer. FDA is soliciting public feedback on precisely this issue, i.e., "the benefits and challenges of [using] ... a suffix derived from the name of the license holder."

By contrast, the Biosimilars Council, a division of the Generic Pharmaceutical Association was disappointed with any distinctive names. It argued that FDA's "naming conventions warrant serious scrutiny for their potential to erect barriers to patient access to new, more affordable medicines, and jeopardizes their safety." The Biosimilars Counsel said that "[a]dding a random collection of letters to the product's nonproprietary name confers no additional safety benefit, and in fact would require the healthcare professional to be armed at all times with a code-breaking reference." The Academy of Managed Care Pharmacy (AMCP) also voiced its disappointment with FDA's decision to use distinctive nonproprietary names. AMCP expressed "concern[] that any departure from the currently accepted nonproprietary naming system will create confusion amongst healthcare practitioners and patients, have negative effects on the ability to ensure safe dispensing and tracking, and result in lower market adoption and cost-savings."

The FDA's draft guidance and proposed rule will undoubtedly receive significant public comment before they are finalized. In the meanwhile, patients and healthcare providers are satisfied with FDA's middle-road approach.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.